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Introduction: This randomized phase II study investigated pem-
etrexed in combination with the epidermal growth factor receptor
(EGFR)-targeting monoclonal antibody matuzumab compared with
pemetrexed alone as second-line therapy for patients with advanced
non-small cell lung cancer.
Methods: Patients received pemetrexed 500 mg/m2 every 3 weeks
either alone (n  50) or in combination with matuzumab at either
800 mg weekly (n  51) or 1600 mg every 3 weeks (n  47). The
primary end point was objective response, as assessed by an inde-
pendent review committee.
Results: Tumor EGFR expression was detected in 87% of randomized
patients. The objective response rate for the pooled matuzumab-treated
arms was 11% compared with 5% for pemetrexed alone (p  0.332).
Apart from one patient in the pemetrexed alone group, all responses
occurred in patients whose tumors expressed EGFR. The objective
response rate for patients receiving weekly matuzumab was 16%
compared with 2% for those receiving matuzumab every 3 weeks.
There was also a trend for improved overall survival in patients
receiving matuzumab weekly versus every 3 weeks (12.4 months
versus 5.9 months, respectively, versus 7.9 months for pemetrexed
alone). The combination of pemetrexed and matuzumab demonstrated
an acceptable safety profile, with the most common grade 3/4 adverse
event being neutropenia.
Conclusion: Although the analysis on the pooled matuzumab-
treated arms did not demonstrate a statistically significant improve-
ment in objective response for the addition of matuzumab to pem-
etrexed compared with pemetrexed alone, the trends for
improvement in objective response and overall survival for pem-
etrexed plus weekly matuzumab compared with pemetrexed alone
warrant confirmation in additional clinical trials.
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The majority of patients with non-small cell lung cancer(NSCLC) have locally advanced or metastatic disease at
presentation.1 First-line chemotherapy for patients with good
performance status generally comprises a platinum-based che-
motherapy doublet, with different doublets delivering similar
levels of efficacy.2–4 The addition of certain monoclonal anti-
bodies to first-line regimens has been shown in randomized
studies to improve overall survival in this setting. Compared
with chemotherapy alone, bevacizumab, specific for vascular
endothelial growth factor, improved survival when combined
with paclitaxel and carboplatin in patients with nonsquamous
cell carcinoma (hazard ratio [HR]: 0.79; p  0.003)5,6 and
cetuximab, specific for the epidermal growth factor receptor
(EGFR), improved survival when combined with cisplatin and
vinorelbine in a broad patient population unselected according to
NSCLC histology (HR: 0.871; p  0.044).7
After the failure of first-line treatment, second-line
chemotherapy options include single-agent treatment with
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docetaxel or the antifolate antimetabolite, pemetrexed.8–10 The
EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib,
are also effective as single agents in this setting.11–13 EGFR is
expressed by the majority of NSCLCs, and some tumors have an
increased EGFR gene copy number.14,15 EGFR is also somati-
cally mutated in a subset of NSCLCs, with the presence in the
tumor of an EGFR kinase domain activating mutation being
both a favorable prognostic indicator for patients receiving
chemotherapy and also a predictive marker for clinical benefit in
relationship to EGFR TKIs.16–19 Nevertheless, EGFR mutation
status is not predictive for the efficacy of cetuximab in the
first-line treatment of NSCLC.20
Clinical studies have, therefore, validated EGFR as an
effective anticancer target in both the first- and second-line
treatment of patients with NSCLC. Matuzumab (EMD
72000)21 is a recombinant, humanized, immunoglobulin G1
monoclonal antibody, which interacts with the ligand-binding
domain of EGFR, sterically preventing domain rearrange-
ment and the local conformational changes required for
high-affinity ligand binding and receptor dimerization.22 In
addition to blocking EGFR-associated downstream signal-
ing,23 matuzumab also induces an antitumor antibody-depen-
dent cell-mediated cytotoxicity response.24 Matuzumab has
demonstrated in vivo activity against human tumor xeno-
grafts, both as a single agent and in combination with con-
ventional chemotherapeutic compounds.25–27
Phase I studies established that matuzumab mono-
therapy was active and well tolerated at weekly doses of up to
1600 mg28 and when administered in combination with pac-
litaxel29 or gemcitabine,30 at weekly doses of 800 mg. When
given in combination, matuzumab did not aggravate the
typical side effects of the cytotoxic agents. Pemetrexed is
approved for the second-line treatment of advanced NSCLC
and has established activity and safety profiles. Thus, the
risk-benefit relationship for the combination of matuzumab
and pemetrexed was regarded as favorable. This phase II
study was, therefore, designed to investigate the activity and
tolerability of pemetrexed plus matuzumab compared with
pemetrexed alone in previously treated patients with NSCLC.
To define the most appropriate dose and schedule for future
studies, two dose groups for matuzumab (800 mg every week
and 1600 mg every 3 weeks) were evaluated. The study was
to be discontinued if new findings arose that indicated a
relevant deterioration of the risk-benefit relationship.
PATIENTS AND METHODS
Key Eligibility Criteria
Patients aged 18 years or older, with a life expectancy
12 weeks, an Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1, and histologically or cytologically
confirmed NSCLC that had progressed on or after first-line
platinum-based chemotherapy for stage IIIB/IV disease were
eligible. Patients had to have at least one measurable lesion
according to modified World Health Organization criteria,
and those with stage IIIB disease were required to have no
clinically significant pleural effusion, unless that pleural ef-
fusion could be effectively drained before admission into the
study. A chemotherapy-free interval of at least 3 weeks
between the end of first-line chemotherapy and start of the
study treatment had to have elapsed. The availability of a
tissue or cytology sample for the determination of EGFR
expression was a requirement, as was adequate organ func-
tion at baseline, as determined by serum creatinine 1.5 
upper limit of normal (ULN; in the case of borderline values,
clearance had to be 45 ml/min); total bilirubin 1.5 
ULN; alanine aminotransferase/aspartate aminotransferase
2.5  ULN (patients with liver metastases required alanine
aminotransferase/aspartate aminotransferase 5  ULN);
absolute neutrophil count 1500/mm3; platelet count
100,000/mm3; and hemoglobin 10 g/dl.
Patients were not eligible if they had participated in
another clinical study within 30 days before the start of study
treatment or received radiotherapy or major surgery within 30
days before the start of study treatment, had received prior
treatment with EGFR-directed therapy or pemetrexed, or if they
had a weight loss 10% within 12 weeks before the start of
study treatment. They were also excluded if they were pregnant/
lactating or had documented or symptomatic brain metastases,
leptomeningeal disease, a preexisting grade 2 skin disorder
(except for alopecia), and a concurrent malignancy or invasive
carcinoma diagnosed within the past 5 years (except for ade-
quately treated basal cell carcinoma of the skin or in situ
carcinoma of the cervix) or if the patient had any disease that, in
the investigator’s opinion, should exclude them from the study.
Patients should not have a history of significant cardiovascular,
neurologic or psychiatric disorder, or autoimmune disease with
significant organ involvement.
Study Design
This was an open-labeled, multicenter, randomized, con-
trolled, phase II study with three parallel treatment groups.
Patients were randomized centrally to receive pemetrexed alone
(500 mg/m2 intravenous [IV] infusion over 10 minutes, day 1,
every 3 weeks) or in combination with matuzumab (as either an
800 mg IV infusion over 1 hour, once every week or a 1600 mg
IV infusion over 1 hour, once every 3 weeks). An observation
period of at least 1 hour was specified between the end of the
matuzumab infusion and the start of pemetrexed administration
when these treatments were given on the same day. Pemetrexed
was administered with dexamethasone, 4 mg twice daily, orally,
the day before, the day of, and the day after infusion; vitamin
B12 administered by intramuscular injection, as one injection of
1000 g during the week preceding the first dose of pemetrexed
and every 9 weeks thereafter; and folic acid, as daily oral doses
of 350 to 1000 g, with at least 5 daily doses taken during the
7-day period preceding the first dose of pemetrexed and con-
tinuing daily throughout treatment, up to 21 days after the last
dose of pemetrexed.
Treatment was continued until disease progression or
the occurrence of unacceptable toxicity. If one treatment was
stopped due to agent-related toxicity, patients in the combi-
nation therapy groups could continue to receive the other
treatment as monotherapy. The study protocol was approved
by independent ethics committees at each center, and the
study was conducted in accordance with the principles estab-
lished in the Declaration of Helsinki. All patients provided
written, informed consent before screening.
Schiller et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1978
The safety/intention to treat (ITT) population was de-
fined as all patients who were randomized and received at
least one infusion of study treatment. The per protocol (PP)
population was defined as all patients who were randomized
and received at least two cycles of study treatment (except in
the case of death or disease progression, as determined by an
independent review committee [IRC], in the first two cycles
of treatment); who had a baseline tumor assessment and at
least one postbaseline tumor assessment; and who had no
major protocol violation.
The primary study objective was to evaluate tumor
response (as assessed by the IRC) for two different regimens
of matuzumab in combination with pemetrexed (analysis of
pooled arms) in comparison with pemetrexed alone in pa-
tients in the PP population with stage IIIB/IV NSCLC.
Secondary objectives were to assess tumor response as de-
termined by the investigators; overall survival; progression-
free survival (PFS); duration of response; safety and tolera-
bility; and quality of life (QoL).
Study Assessments
Tumor response was evaluated according to the modi-
fied World Health Organization criteria by radiologic assess-
ment every 6 weeks (3 days) during study treatment,
regardless of any treatment delays, until disease progression.
Patients who stopped treatment before disease progression
remained in the study and continued to be assessed radiolog-
ically for tumor response every 6 weeks. The IRC conducted
a blinded radiologic review of the images of all patients to
determine best overall response and response duration using
criteria based on a separate charter. All images were reviewed
by two IRC radiologists. If the reviews were not in accor-
dance, a third radiologist decided tumor status. Toxicity was
assessed at each chemotherapy visit (every 3 weeks) and
weekly in the group receiving weekly matuzumab. Complete
blood counts (including platelets and absolute neutrophil
count) were assessed weekly while the patient was on pem-
etrexed. The Lung Cancer Symptom Scale was used to
measure QoL in relationship to six major symptoms. The
questionnaire was completed at baseline, at 6, 12, 24, 36, and
48 weeks after the start of treatment, and at the end of
treatment visit. After the end of study visit (6 weeks after
the last study treatment), survival data were collected every 3
months. Information on subsequent anticancer treatments was
also collected up to the first follow-up visit.
EGFR expression was assessed (DakoCytomation
pharmDx immunohistochemistry kit) by a pathologist at a
central facility. Tumors that stained with an intensity 0
were scored as EGFR detectable.
Statistical Methods and Considerations
The primary target variable was the objective tumor
response as assessed by the IRC. Assuming a response rate of
10% with pemetrexed alone and 31% in the pooled matu-
zumab treatment arms, it was calculated that 40 patients per
arm would give a 70% power to detect an increase in the
response rate from 10 to 31% at a two-sided alpha level of
0.05. Allowing for dropout rate of 20%, randomization (1:
1:1) of 150 patients was planned.
Analyses of efficacy were performed for both the PP
and safety/ITT populations, with the PP population being the
primary analysis set. Fisher’s exact test was performed be-
tween the pooled matuzumab and pemetrexed arms for the
difference in responders. All analyses of safety and QoL were
performed using the safety/ITT population.
For time-to-event variables, Kaplan-Meier curves31
were drawn by treatment group to visualize the effect of the
treatment. The HRs between treatments and their 95% CIs
and associated p values were computed using a Cox-propor-
tional hazards model with treatment as a factor. HRs are
presented in each case as experimental versus control arm.
Safety and tolerability were summarized descriptively, with
adverse events (AEs) and laboratory data classified according
to the National Cancer Institute-Common Terminology Cri-
teria for Adverse Events (version 3.0).
RESULTS
Patient Demographics
The first patient was enrolled on August 16, 2005. The
data cutoff for survival analyses was July 16, 2007, which
FIGURE 1. Consolidated Standards of Reporting Trials dia-
gram: disposition of subjects at time of data cutoff (July 16,
2007). *Two patients did not receive any study treatment
after randomization. One patient died after randomization
and before first infusion, and one patient was withdrawn
due to disease progression after randomization and before
first infusion. ITT, intention to treat; PP, per protocol.
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was 5 months after the last patient had entered the study. Of
234 patients from 46 centers who were initially screened, 150
were subsequently randomized to three treatment groups
(Figure 1). After randomization, two patients in the pem-
etrexed plus matuzumab every 3 weeks group did not receive
any study treatment and were, therefore, excluded from the
safety/ITT population. The most frequent reason for treat-
ment discontinuation during the study was disease progres-
sion (65% of patients). Baseline demographic and disease
characteristics were broadly similar between the treatment
groups, although a higher percentage of patients had adeno-
carcinoma and a lower percentage squamous cell carcinoma
in the pemetrexed plus weekly matuzumab group compared
with the other groups. EGFR expression was detected in the
tumor tissue of 92% of patients who received pemetrexed
alone, 92% of patients who received pemetrexed plus matu-
zumab weekly and 76% of patients who were randomized to
receive pemetrexed plus matuzumab every 3 weeks (Table 1).
The PP population comprised a total of 130 patients, 44
who received pemetrexed alone, 44 who received pem-
etrexed plus matuzumab weekly, and 42 who received
pemetrexed plus matuzumab every 3 weeks (Table 1).
TABLE 1. Patient and Disease Characteristics at Baseline in the Safety/ITT Population and Reasons for
Exclusion from the Per Protocol Population
Pemetrexed Alone,
n  50
Pemetrexed Plus Matuzumab
(800 mg/wk), n  51
Pemetrexed Plus Matuzumab
(1600 mg/3 wk), n  47
Ethnic origin, n (%)
White 47 (94) 47 (92) 47 (100)
Black 3 (6) 4 (8) 0
Gender, n (%)
Male 33 (66) 35 (69) 27 (57)
Female 17 (34) 16 (31) 20 (43)
Age (yr)
Median 61 62 63
Range 37–83 48–81 46–78
Histology of primary, n (%)
Adenocarcinoma 23 (46) 30 (59) 22 (47)
Squamous cell carcinoma 18 (36) 11 (22) 17 (36)
Undifferentiated carcinoma 3 (6) 3 (6) 0
Large cell carcinoma 1 (2) 2 (4) 2 (4)
Adenosquamous carcinoma 2 (4) 0 0
Other 3 (6) 5 (10) 6 (13)
Stage at study entry, n (%)
IIIB 6 (12) 8 (16) 6 (13)
IV 44 (88) 42 (82) 41 (87)
Missing 0 1 (2) 0
EGFR expression status, n (%)a,b
EGFR detectable 46 (92) 47 (92) 37 (76)
EGFR nondetectable 3 (6) 4 (8) 9 (18)
Not assessed 1 (2) 0 3 (6)
Prior therapy, n (%)
First-line chemotherapy for advanced NSCLC 50 (100) 51 (100) 47 (100)
Prior best response  CR, PR, or SD 34 (68) 37 (73) 33 (70)
Prior nonresponse (PD) 16 (32) 14 (27) 14 (30)
Radiotherapy 19 (38) 25 (49) 29 (62)
Per protocol population, n
No. of patients 44 44 42
Excluded ITT patients 6 7 5
Reasons for exclusionc
Major protocol violation 1 2 3
2 cycles of study treatment 6 6 2
No postbaseline assessment availabled 4 4 1
a Randomized patients (n  49 for group receiving pemetrexed and matuzumab every 3 wk).
b Each tumor sample that stained for EGFR with an intensity greater than zero, as evaluated by a pathologist at a central facility, was scored as EGFR
detectable.
c More than one may apply.
d Except in the case of death or disease progression.
CR, complete response; EGFR, epidermal growth factor receptor; ITT, intention to treat; PD, progressive disease; PR, partial response; SD, stable disease.
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Patients were excluded from the PP population (except in
the case of death or PD) most frequently because they had
received less than two cycles of study treatment (14
patients, 9%) and/or had not undergone any postbaseline
assessment (nine patients, 6%). Six patients were excluded
due to major protocol violations.
Treatment Exposure
Exposure to study treatment in the safety/ITT popula-
tion is summarized in Table 2. More than 80% of patients in
each of the study arms received two or more cycles of
pemetrexed alone or pemetrexed in combination with matu-
zumab, with more than 20% of patients in each arm receiving
six or more cycles of treatment. The median duration of
pemetrexed treatment was 66.5 days for patients receiving
pemetrexed alone and 42.0 and 46.0 days for patients receiv-
ing pemetrexed plus matuzumab administered weekly and
every 3 weeks, respectively.
After the completion of study treatment, 19 patients
(37%) in the pemetrexed plus weekly matuzumab group
received further chemotherapy (any) and 10 patients (20%)
continued with an anti-EGFR treatment comprising any
EGFR TKI, compared with 10 (20%) and 15 patients (30%)
in the pemetrexed alone group and 12 (26%) and five (11%)
patients in the pemetrexed plus matuzumab every 3 weeks
group, respectively (Table 2). There was, therefore, some
degree of imbalance in poststudy therapy between the treat-
ment groups.
Efficacy
In the primary IRC analysis on pooled matuzumab
treatment arms, objective response rates for the PP population
were higher in the combined group (weekly/every 3 weeks)
of patients who received pemetrexed plus matuzumab com-
pared with those who received pemetrexed alone (n  86
versus n  44; 11% versus 5%, respectively). Nevertheless,
this difference was not statistically significant (p  0.332).
Rates of disease control were similar in the two groups (36%
versus 41%, respectively). Considering the three individual
treatment groups in the secondary analyses of the safety/ITT
population (Table 3), objective response as assessed by the
IRC was observed most frequently in patients receiving
pemetrexed plus weekly matuzumab (16%) compared with
those receiving pemetrexed alone (4%) or pemetrexed plus
matuzumab administered every 3 weeks (2%). Rates of dis-
ease control were similar in the different treatment groups
(33% versus 36% versus 34%, respectively). The same trend
was observed for objective response based on investigator
assessment.
Subgroup analyses revealed that tumor responses, all of
which were partial, were confined to the group of patients
who had responded to prior chemotherapy. Except for one
patient in the pemetrexed alone group, all responses occurred
in patients whose tumors were scored as EGFR detectable.
Somatic EGFR coding sequence mutations were identified in
the tumors of 4 of 69 patients (6%); none of these tumors had
responded to treatment (data not shown, methods available on
request).
Median PFS time was similar for all three treatment
groups (Figure 2A). Median overall survival time was 7.9
months (95% confidence interval [CI]: 7.2–9.9) for the pem-
etrexed alone group and 12.4 (95% CI: 8.8, not evaluable)
and 5.9 (95% CI: 3.6–7.2) months for those receiving matu-
zumab weekly or every 3 weeks, respectively (Table 3,
Figure 2B).
TABLE 2. Exposure to Treatment in the Safety/ITT
Population
Pemetrexed
Alone,
n  50
Pemetrexed Plus
Matuzumab (800
mg/wk), n  51
Pemetrexed Plus
Matuzumab
(1600 mg/3 wk),
n  47
Duration of
pemetrexed
treatment (d)
Median 66.5 42.0 46.0
Range 21–385 21–260 21–253
Duration of
matuzumab
treatment (d)
Median 43.0 46.0
Range 7–278 21–253
No. of entered
pemetrexed
cycles, n (%)
1 50 (100) 51 (100) 47 (100)
2 41 (82) 42 (82) 40 (85)
4 24 (48) 20 (39) 19 (40)
6 12 (24) 14 (27) 10 (21)
8 7 (14) 6 (12) 2 (4)
No. of entered
matuzumab
cycles, n (%)
1 51 (100) 47 (100)
2 42 (82) 40 (85)
4 21 (41) 18 (38)
6 15 (29) 12 (26)
8 9 (18) 3 (6)
Cumulative dose
of pemetrexed,
mg/m2
Median 1500.0 1000.0 1000.0
Range 500–9000 500–5500 500–6000
Cumulative dose
of matuzumab
(mg)
Median 4800.0 3200.0
Range 800–30,400 1600–19,200
Poststudy
anticancer
therapy, n (%)
Radiotherapy 2 (4) 3 (6) 1 (2)
Chemotherapy 10 (20) 19 (37) 12 (26)
EGFR TKI 15 (30) 10 (20) 5 (11)
Other 3 (6) 5 (10) 4 (9)
ITT, intention to treat; EGFR TKI, epidermal growth factor receptor tyrosine kinase
inhibitor.
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Safety
Treatment-related rash (grade 1/2) was markedly
more common in patients who received pemetrexed plus
matuzumab weekly (37% of patients) or every 3 weeks
(43% of patients; one patient grade 3) compared with those
receiving pemetrexed alone (14% of patients). The inci-
dence of grade 3/4 treatment-related AEs was broadly
comparable between the three treatment groups (Table 4).
The most common grade 3/4 treatment-related AE was
neutropenia (16% of patients overall), reported for 22% of
patients who received pemetrexed plus weekly matuzumab
compared with 15% and 12% of those receiving pem-
etrexed plus matuzumab every 3 weeks or pemetrexed
alone, respectively. Treatment-related fatigue and diarrhea
were reported at grade 3/4, respectively, for one (2%) and
no patients who received pemetrexed alone; four (8%) and
one (2%) patient who received pemetrexed plus matu-
zumab weekly; and one (2%) and no patients who received
pemetrexed plus matuzumab every 3 weeks. Nine patients
discontinued treatment due to AEs. In four cases, these
were deemed to be possibly related to matuzumab (or
pemetrexed).
FIGURE 2. Survival analyses. Kaplan-Meier plots for progression-free survival (A) and overall survival (B) according to study
arm. Group A received pemetrexed alone; group B, pemetrexed plus weekly matuzumab; and group C, pemetrexed plus
matuzumab every 3 weeks.
TABLE 3. Response Rate, Progression-Free Survival, and Overall Survival According to Treatment (Safety/ITT
Population)
Pemetrexed Alone,
n  50
Pemetrexed Plus Matuzumab
(800 mg/wk), n  51
Pemetrexed Plus Matuzumab
(1600 mg/3 wk), n  47
Best overall response,a n (%)
Complete response 0 0 0
Partial response 2 (4) 8 (16) 1 (2)
Stable disease 16 (32) 9 (18) 15 (32)
Progressive disease 19 (38) 23 (45) 20 (43)
Not evaluable 13 (26) 11 (22) 11 (23)
Objective response rate,b n (%) 95% CI 2 (4) 1–14 8 (16) 7–29 1 (2) 0–11
Disease control rate,c n (%) 95% CI 18 (36) 23–51 17 (33) 21–48 16 (34) 21–49
Progression-free survivala
No. of events 33 35 37
Hazard ratiod 95% CI 0.96 0.59–1.56 1.46 0.90–2.38
Median (mo) 95% CI 2.7 1.6–4.4 2.3 1.5–3.8 2.5 1.4–2.9
Overall survival
No. of events 25 21 30
Hazard ratiod 95% CI 0.67 0.37–1.21 1.66 0.97–2.86
Median (mo) 95% CI 7.9 7.2–9.9 12.4 8.8-NE 5.9 3.6–7.2
a Independent review committee assessments.
b Complete responses  partial responses.
c Complete responses  partial responses  stable disease.
d Pemetrexed plus matuzumab versus pemetrexed alone.
CI, confidence interval; ITT, intention to treat; NE, not evaluable.
Schiller et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1982
Sixteen patients died within 30 days of the last admin-
istration of study treatment, with nine deaths linked to disease
progression. Seven deaths were due to AEs: one patient in the
pemetrexed alone group died due to sepsis, two patients in
the pemetrexed plus weekly matuzumab group died due to
respiratory failure and exsanguination, respectively, and four
patients in the pemetrexed plus matuzumab every 3 weeks
group died due to pneumonia and respiratory failure; renal
failure; hemorrhage; and pulmonary embolism, respectively.
None of these seven deaths were thought to be related to
matuzumab, with two possibly related to pemetrexed (sepsis
and pneumonia/respiratory failure).
Quality of Life
At baseline, weeks 6, 12, 24, 36, and at the end of
treatment, 91%, 51%, 28%, 10%, 2% and 46%, respectively,
of patients in the safety/ITT population completed QoL
questionnaires. Changes in QoL parameters between baseline
and cycle 2 were variable in pattern, and it was not clear
whether they favored any of the treatment groups (Table 5).
The data variability and the magnitude of changes between
visits impeded a meaningful evaluation of QoL in relation-
ship to the different regimens.
DISCUSSION
In the primary analysis of the PP population, this study
failed to demonstrate a statistically significant increase in
objective response rate for the addition of matuzumab to
pemetrexed compared with pemetrexed alone (11% versus
5%, respectively, p  0.332). Nevertheless, secondary anal-
ysis by treatment group in the safety/ITT population indicated
that the majority of the responses in the matuzumab arms had
occurred in patients receiving matuzumab at 800 mg weekly
(objective response rate of 16% compared with 4% for the
pemetrexed alone group). The risk of disease progression was
similar for patients receiving pemetrexed plus weekly matu-
zumab compared with pemetrexed alone (HR: 0.96), but the
risk of death at any given time point was notably lower (HR:
0.67, median overall survival 12.4 months [95% CI: 8.8-not
evaluable] versus 7.9 months [95% CI: 7.2–9.9], respec-
tively), suggesting an increase in overall survival for the
pemetrexed plus matuzumab 800 mg weekly regimen over
pemetrexed alone.
Although objective response rate was chosen as the
primary end point for this study, it has been argued that
alternative rapidly assessable end points may be more appro-
priate indicators of anticancer activity in phase II trials,
particularly perhaps those investigating the newer targeted
agents.32–34 Indeed, despite the observation that overall sur-
vival seemed to be improved in the weekly pemetrexed
compared with pemetrexed alone group, the possibility that
this was related to imbalances in poststudy anticancer therapy
cannot be discounted, especially because PFS was similar for
all treatment groups. Recent analyses have also indicated that
the survival benefit of pemetrexed is restricted to patients
whose disease is of nonsquamous histology.35 In considering
the survival data in this study, it should, therefore, be noted
that slightly fewer patients in the group receiving pemetrexed
plus weekly matuzumab had squamous cell carcinomas
(22%) compared with the other two groups (36%). Neverthe-
less, whether this factor contributed significantly to the im-
proved survival in the pemetrexed plus weekly matuzumab
group cannot be determined, as the number of patients is too
small to permit meaningful subgroup analysis. In contrast to
the data for weekly administration, there was no evidence
from this study that the addition of matuzumab at 1600 mg
every 3 weeks to pemetrexed provided any clinical benefit
compared with pemetrexed alone.
The combination of pemetrexed and matuzumab was
generally well tolerated, and the study provided no indication
that the coadministration of both drugs aggravated the safety
profile of the individual agents. The overall incidence of
treatment-related grade 3/4 AEs was similar across the patient
groups (34–39%). Previous studies have identified skin rash
as a common side effect of matuzumab treatment, with such
reactions typically reaching only grade 1 or 2.23,28–30 Treat-
ment-related grade 1/2 rash was also common in the matu-
zumab arms of this study (rash reported for 37% of patients
receiving the weekly regimen and 43% of patients receiving
the every 3 weeks regimen compared with 14% of patients
receiving pemetrexed alone). Such skin reactions are a char-
acteristic side effect of EGFR-targeted agents.36
The phase III FLEX study demonstrated that the addi-
tion of cetuximab to a standard first-line therapy for advanced
NSCLC statistically significantly improved overall survival
compared with chemotherapy alone.7 This large randomized
study, therefore, provided further data confirming EGFR as
an effective molecular target in the treatment of advanced
disease. The results of this study suggest that the EGFR-
targeting monoclonal antibody matuzumab may prove to be
most effective in this setting when administered weekly at
800 mg.
In conclusion, this study failed to demonstrate that the
addition of matuzumab to pemetrexed as second-line therapy
for NSCLC significantly improved objective response com-
TABLE 4. Treatment-Related Grade 3/4 Adverse Events
Experienced by 5% of Patients in Any Treatment Group
According to Preferred Terms (Safety/ITT Population)
Preferred Term,a
n (%)
Pemetrexed
Alone,
n  50
Pemetrexed Plus
Matuzumab
(800 mg/wk),
n  51
Pemetrexed Plus
Matuzumab
(1600 mg/3 wk),
n  47
Any grade 3/4 adverse
event
25 (50) 29 (57) 29 (62)
Any treatment-
related grade 3/4
adverse event
17 (34) 20 (39) 18 (38)
Neutropenia 6 (12) 11 (22) 7 (15)
Lymphopenia 0 1 (2) 5 (11)
Fatigue 1 (2) 4 (8) 1 (2)
Leukopenia 1 (2) 3 (6) 3 (6)
Thrombocytopenia 0 1 (2) 3 (6)
a Events were coded according to the Medical Dictionary for Regulatory Activities
version 9.0.
ITT, intention to treat.
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pared with pemetrexed alone. Nevertheless, a preplanned
subgroup efficacy analyses revealed some evidence of benefit
for pemetrexed plus weekly matuzumab compared with pem-
etrexed alone or pemetrexed plus matuzumab given every 3
weeks. There were no marked differences between the treat-
ment groups with respect to safety.
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